English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduIn 2017, a Children’s Hospital Los Angeles team led by Jesse Berry, MD, pioneered the development of the first liquid biopsy for retinoblastoma, the most common childhood eye cancer. But while the biopsy information—taken from the aqueous humor fluid in the front of the eye—could be studied in the lab, it wasn’t yet able to be applied to patient care.
Tag: Retinoblastoma
MD Anderson Research Highlights for February 1, 2023
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Children’s Hospital Los Angeles Identifies Molecular Markers to Increase Precision in Treatment of Retinoblastoma
Retinoblastoma is a cancer of the eye that occurs in infants and toddlers and can lead to loss of vision, loss of one or both eyes, and even death. Unlike most tumors, these cannot be biopsied because of the risk of spreading cancer to the rest of the body. In 2017, Jesse Berry, MD, surgeon and ocular oncologist at Children’s Hospital Los Angeles, discovered that fluid removed from the eye during treatment of retinoblastoma contained tumor DNA and functioned as a liquid biopsy—providing information about the tumor and opening the door to earlier diagnosis and treatment.
Retinoblastoma resource: Researchers create more accurate research model
St. Jude Children’s Research Hospital scientists have created a model of the rare pediatric eye cancer that more closely mimics the biology of patient tumors.
By age 10, retinoblastoma patients’ learning and life skills rebound
St. Jude retinoblastoma researchers studied how survivors fared years later at home and at school.